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Running Head: Inhaled mannitol study in CF Despite recent advances in treatment, patients with cystic fibrosis continue to experience a progressive decline in lung function and premature mortality. Mannitol is a dry powder agent with osmotic properties that hydrates the airway surface and changes mucus rheology, thus aiding mucociliary clearance from the lungs.
What This Study Adds to the Field
This double-blind randomized Phase III trial demonstrates that adding mannitol to standard therapy produces sustained improvement in lung function for 26 to 52 weeks. Quantitative microbiology showed added safety. There are numerous therapies directed toward the treatment of the lungs to slow the progression of the disease. These treatments include antibiotics, anti-inflammatory agents, mucolytics and agents and maneuvers that enhance airway clearance (3, 4, 5) . Current treatment guidelines recommend inhaled dornase alfa (rhDNase, Pulmozyme, Genentech, San
Francisco, CA) and inhaled hypertonic saline (an osmotic agent that may help to restore the airway surface liquid) to improve lung function and reduce exacerbations (6) .
However, the number of treatments prescribed for CF patients and the amount of time it takes to accomplish them imposes a significant burden on the patients. There remains a need for effective therapies that can improve mucociliary clearance and decrease the time burden of disease associated with CF. When inhaled, mannitol (a sugar alcohol) is believed to increase surface liquid in the airways by creating an osmotic gradient that encourages movement of water into the lumen, and thereby enhancing mucociliary clearance (7) . Mannitol is a dry powder and is inhaled from a simple, disposable, capsule-based dry-powder inhaler (DPI). As such, it has the potential to be a more convenient alternative as it does not require refrigeration, nebulization, equipment cleaning or sterilization.
In a small, double-blind crossover study in which 39 patients with mild-moderately severe CF inhaled 420 mg mannitol bid and placebo (non-respirable mannitol; each for 2 weeks), the active treatment produced a significantly greater improvement in forced expiratory volume in The purpose of this second international phase III study was to determine whether long-term (26-week) administration of mannitol improves FEV 1 . FEV 1 was used as the primary outcome variable, as it is the strongest clinical predictor of survival in patients with CF (11, 12, 13) .
In addition to extending our understanding of potential benefits for lung function, the study explored the effect of mannitol treatment on the frequency of pulmonary exacerbations, which is known to associate with accelerated loss of lung function and decreased survival (14, 15, 16) Given a possible influence of mannitol on lung microbiology, quantitative microbiology was explored.
METHODS
This was a 26-week double-blind, randomized, controlled trial of inhaled mannitol (Pharmaxis, Sydney NSW, Australia) 400 mg bid versus a control of mannitol 50 mg bid followed by a 26-week open-label extension during which all subjects received active treatment. Low dose mannitol was chosen as the placebo following discussion with regulatory agencies and in accordance with the results of the dose-finding study (17) .
Selection of Patients
The study was conducted in full accordance with the current revision of the Declaration of 
Randomization and Blinding
Patients were randomized to active treatment or the control arm in a 3:2 ratio. Randomization was stratified by country and use of dornase alfa.
Study drug
Patients were assigned to receive ten capsules of inhaled mannitol 40 mg (mannitol group) or 
Statistics and Statistical Methods
The study was designed to have 80% power to detect a change from baseline of 79. and visit by treatment group interaction term for the MMRM models only, and, for pulmonary exacerbations, PDPEs and hospitalization, prior history of these events.
A single pre-planned interim analysis was conducted during the study and the Haybittle-Peto stopping rule was to be employed to determine whether the study was to terminate early. As a 
RESULTS

Patient Characteristics
The study was conducted between September 2008 and April 2010. Figure 1 shows that of the 342 potentially eligible patients, 318 (93%) completed and passed the MTT and were randomized, of whom 305 patients began study treatment. Patient demographics are shown in Table 1 , and reveal that patients in the two arms of the study were well matched.
One important difference between treatment groups was the mean change in FEV 1 measures from the screening visit to the baseline visit (Visit 1), which dropped in the control group but remained stable in the mannitol group (Table 1) .
Compliance and Completion
At each visit, patients returned all used and unused blister packs of active drug or control.
These were reconciled against numbers dispensed. Compliance with protocol treatment was defined as use of 60% or more of drug dispensed. By this criterion, compliance was good in control group discontinued the study due to AEs, with increased cough being the most frequently cited event.
Efficacy
Change in FEV 1 (mL) and FEV 1 (% predicted)
The mean improvement in FEV 1 was greater in the mannitol group than the control group (106.5 vs. 52.4 mL, p=0.059) see Figure 2a . The relative change from baseline FEV 1 (mL) in the mannitol group was 8.22% while that in the control group was 4.47% (effect between groups 3.75%, p=0.029). There was a difference in the secondary endpoint of absolute Therefore, in a post-hoc sensitivity analysis, baseline FEV 1 was calculated as the mean of the values at screening and at Visit 1 (rather than taking the Visit 1 value alone). Using these baseline-corrected values, the overall increase in absolute FEV 1 seen in the mannitol group was significantly greater than that in the control group (difference 71.1 mL, p=0.008). A post hoc examination of the relative change in FEV 1 (%) using the mean of the screening and baseline FEV 1 (mL) value showed an overall treatment effect that favored the mannitol group (difference 3.97%, p=0.008). 
FVC
In the mannitol group, FVC increased 136.3 mL compared to a 65.0 mL increase in the control group. There was an overall increase of 71.4 mL in FVC in the mannitol group compared to the control group (p=0.022) (Figure 2c ).
Pulmonary Exacerbations, Hospitalization and Other Outcomes
Over the 26-week period of double-blind treatment, patients in the mannitol group experienced fewer pulmonary exacerbations whether protocol-defined (PDPE) or from any cause (Table 3 ), but the difference was not statistically significant. Similar numbers of patients were treated with IV antibiotics for a PDPE in both the mannitol (15.2%) and control (19.0%) groups. Of these acute exacerbations, most were hospitalized (12% and 15.7% respectively). The duration of hospital stay was three days shorter in patients in the mannitol group. There was no significant difference in quality of life from baseline for either treatment group or between treatment groups for any of the quality of life domains. At Visit 1, patients in the Bronchitol group cleared more sputum during and for 30 minutes post Bronchitol administration than patients in the control group. The median sputum weights were 2.7 vs. 1.7
grams respectively (p=0.04). At Week 14, patients in the Bronchitol group cleared less sputum than at Visit 1, but still more than the control group. Median weights were 2.0 vs. 1.5
grams respectively (p=0.26).
Adverse Events
The proportion of patients reporting AEs was similar in the mannitol and control groups (89.7% and 87.6% of patients, respectively). Headache was reported by 14.1% of mannitol subjects and 18.2% of control subjects, while 15.2% of mannitol subjects experienced cough (control 13.2%). Hemoptysis reported as either an AE or as part of an exacerbation was similar in the treatment arms at 11.4% vs 10.7% in the mannitol and control groups, respectively).
There was one death in the study population: a patient in the control group died approximately 3 months after discontinuing study treatment because of a serious AE (pneumothorax). The death was considered unrelated to treatment.
Clinically significant findings regarding vital signs, the physical exam, hematology and biochemistry were generally similar in the two treatment groups and related to the underlying disease. Abnormal white cell count was the most common hematological abnormality, and seen in 5 patients from each treatment group. There were no significant findings for liver function enzymes or diabetes control.
Microbiology
There were no qualitative changes in microbiology results from baseline in either group.
Mannitol and control groups showed no change from baseline to Week 26 in the frequency of sputum colonization by S. aureus or P. aeruginosa. There was no change in the number of colony forming units per gram sputum. Data are given in Table 5a and b and c. 
DISCUSSION
We demonstrated a 105 mL mean improvement in the FEV 1 of the mannitol-treatment group, an 8.2% improvement from baseline. However, for the primary end point for the study, i.e.
the difference in absolute FEV 1 between the treated and control groups over 26 weeks of the study, statistical significance was narrowly missed (although was significant by relative difference). A second point is that the control arm received a lower dose of the same drug. It was felt that 50 mg would not be clinically effective because of results from the dose escalation study (17) where 40 mg dose seemed to have no effect on FEV 1 . However, it is possible that the lower dose of mannitol may have some benefit, but not as much efficacy as the higher dose, and this finding emerged because of the larger number of patients in this study. The improvement in FEV 1 at the lower dose of mannitol (50 mg) does appear to contribute to the lack of statistically significant absolute (mL) difference between the two doses of mannitol.
As for the other spirometric measures (% predicted FEV 1 and FVC) the 400 mg inhaled mannitol dose resulted in a statistically and clinically significant average improvements in lung function over the treatment period compared to control.
There were fewer pulmonary exacerbations in the mannitol group, although this did not reach statistical significance. This study was not powered to observe an effect on acute pulmonary exacerbations as they can be relatively uncommon in the course of six months. Prior multicenter trials have sometimes detected a decrease in the number of acute pulmonary exacerbations or a delay to the next pulmonary exacerbation (20, 23). However, in this study all preventative medications against acute exacerbations were continued, and thus we believe that it would be difficult to detect change in acute exacerbations in this study over 6-months.
Overall there was a low rate of acute exacerbations (<1 per year) in the study population and . Interestingly, patients with a higher rate of pulmonary exacerbation in the year preceding the study were more likely to experience a pulmonary exacerbation during the trial, and the historical rate of pulmonary exacerbations in the year prior to treatment was 19.7%
higher among mannitol than among control patients).
Mannitol was well tolerated, and the proportion of patients discontinuing from the study due to AEs was similar between the groups. The AEs reported were generally mild or moderate and consistent with CF and its treatment. Cough was more common in the mannitol than in the control arm and is a known side-effect of this agent. When it contributes to clearance of mucus, cough can be a positive event. However, a small proportion of patients are unable to tolerate it, and cough was the most common treatment-related AE leading to withdrawal. The incidence of severe AEs and serious treatment-related AEs were similar in the two arms of the study. No safety signals of concern were detected.
Hemoptysis is frequently associated with CF exacerbation and therefore many occurrences of hemoptysis were captured as symptoms of pulmonary exacerbation or PDPE but not necessarily as AEs. When hemoptysis reported as a symptom of a pulmonary exacerbation was included in the analysis of hemoptysis AEs, the frequency of hemoptysis was similar overall in both the mannitol and control groups. Inhaled mannitol like hypertonic saline is known to induce bronchospasm in other patient populations. To reduce any potential risk of bronchospasm, a test dose of mannitol was instituted at screening (MTT), and bronchodilator was routinely used prior to inhaled mannitol administration in the study. A small minority of the CF population (6.4%) did not proceed into the study on initial testing due to bronchial In comparing change in FEV 1 with 50 mg (control) and 400 mg of inhaled mannitol over 26 weeks, Figure 2A shows a 54.14 mL absolute difference, and Figure 2B shows a 3.59% difference in relative change in percent predicted FEV 1 . Figure 2C shows a 71.35 mL difference in absolute FVC. Figure   2D shows that the initial control group and the initial treatment group had 84 mL and 87 mL increase in FEV 1 from baseline respectively at the end of a six-month open label period. 
Mannitol Tolerance Test (MTT)
The MTT procedure identified subjects who had airway hyperresponsiveness in response to inhaled mannitol. Airway hyperresponsiveness was determined by measuring the degree of bronchoconstriction that occurs following sequential administrations of inhaled mannitol.
Monitoring Subject Safety during the MTT Procedure
Subjects were monitored during the MTT procedure by following the schedule listed in Table E1 . 
Sample size assumptions and calculations
A total sample size of 250 patients was planned for the CF302 study. 150 patients were to be randomized to receive inhaled mannitol, while 100 were to be randomized to receive control therapy. It was planned that 100 of the patients in the mannitol arm would also be receiving rhDNase, while 50 would not be taking rhDNase. With a dropout rate of 20%, 120 patients in the mannitol arm were expected to complete the study (80 taking rhDNase, 40 not taking rhDNase) and 80 patients in the control arm were expected to complete the study.
The primary hypothesis, that there was no difference in the change from baseline FEV 1 (∆FEV 1 ) between patients taking inhaled mannitol and patients in the control group, was to be analysed using a repeated measures analysis. Age and baseline % predicted FEV 1 were to be included in the model as covariates for each patient.
The CF201 phase II study findings were used as assumptions for determining the power for testing this hypothesis, given the sample size chosen. The ∆FEV 1 for patients taking rhDNase and inhaled mannitol was expected to be 120 mL (SD =200), while the ∆FEV 1 was expected to be 0 mL (SD=200). Given these assumptions, and a type one error rate of 5%, the power to detect a difference of 120 mL in ∆FEV 1 was 96%. When both rhDNase and non-rhDNase patients were taken into consideration, the power to detect the same difference of 120 mL ∆FEV 1 was 98%.
The power estimate provided was obtained from the following formula for the sample size:
In formula 1, ∆ represented the expected difference in ∆FEV 1 between patients in the mannitol arm and the control arm (120 mL). The value σ represented the common standard The formula was reworked to solve for zβ and thereby determine the power of β:
Using formula 2, it was shown that by having 45 patients taking rhDNase in the mannitol arm and 45 patients in the control group, a power of 80% would be achieved.
